Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Change in Account Payables (2018 - 2025)

Inmune Bio's Change in Account Payables history spans 8 years, with the latest figure at $81000.0 for Q2 2025.

  • For Q2 2025, Change in Account Payables fell 2.41% year-over-year to $81000.0; the TTM value through Jun 2025 reached $45000.0, down 26.23%, while the annual FY2024 figure was -$10000.0, 138.46% down from the prior year.
  • Change in Account Payables for Q2 2025 was $81000.0 at Inmune Bio, up from $78000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $83000.0 in Q2 2024 and bottomed at -$84000.0 in Q3 2024.
  • The 5-year median for Change in Account Payables is $0.0 (2021), against an average of $5714.3.
  • The largest annual shift saw Change in Account Payables plummeted 4500.0% in 2023 before it soared 271.43% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at $70000.0 in 2021, then tumbled by 98.57% to $1000.0 in 2022, then tumbled by 4500.0% to -$44000.0 in 2023, then surged by 31.82% to -$30000.0 in 2024, then soared by 370.0% to $81000.0 in 2025.
  • Per Business Quant, the three most recent readings for INMB's Change in Account Payables are $81000.0 (Q2 2025), $78000.0 (Q1 2025), and -$30000.0 (Q4 2024).